Tag Archives: Janssen

TB advocates call on organizations, leaders to work together, speed access to existing treatments for drug resistant tuberculosis

By on .

They would like an answer on March 24 When World TB Day next Tuesday commemorates the discovery in 1882 of the bacteria that causes the disease, announcements and op-ed pieces will note the progress that has been made since, and will certainly call for more. A group of 89 organizations that last week sent a […]

TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

By on .

Last week’s developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility. That good news for multidrug-resistant TB patients, many of whom have run out of other options, was […]

International Partnership for Microbicides, pharmaceutical company agreement sets path for woman-controlled HIV prevention

By on .

The announcement today that Janssen R&D Ireland pharmaceutical company will give the nonprofit International Partnership for Microbicides exclusive worldwide rights to develop, make and market sexual and reproductive health products with the antiretroviral dapivirine was heralded by both organizations as a stride for global public health in general, and HIV prevention for women in particular. The […]